NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01926236,Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers,https://clinicaltrials.gov/study/NCT01926236,ABC06,COMPLETED,The purpose of this study is to determine whether fit patients (with ECOG performance score of 0-1) with advanced biliary tract cancer (ABC) benefit from chemotherapy in the second-line setting (after prior therapy with cisplatin and gemcitabine) in terms of overall survival.,NO,Biliary Tract Cancer|Gallbladder Cancer|Cholangiocarcinoma|Ampullary Cancer,OTHER: Active Symptom Control|DRUG: L-folinic acid|DRUG: 5 FU|DRUG: Oxaliplatin,"Overall survival, Evaluated by monthly follow-up until 12 months after last patient included","Progression-free survival, Clinical progression assessed monthly, radiological progression assessed to RECIST criteria every 12 weeks for patients in the chemotherapy arm., Evaluated by monthly follow-up until 12 months after last patient included|Response rate (chemotherapy arm only), After 12 weeks of treatment|Toxicity (frequency of adverse events and serious adverse events), Events will be classified according to CTCAE V4.03, Evaluated monthly until 12 months after last patient included|Quality of life, Assessed from patient completed questionnaire data: QLQ-C30 and QoL BiL, Evaluated every 3 months until 12 months after last patient included|Costs of health and social care, Evaluated every 3 months until 12 months after last patient included|Health status (Euroqol), Evaluated every 3 months until 12 months after last patient included|Quality adjusted life years (QALYs), Estimated from Euroqol and survival using published utility tariffs, Evaluated every 3 months until 12 months after last patient included",,The Christie NHS Foundation Trust,Cancer Research UK,ALL,"ADULT, OLDER_ADULT",PHASE3,162,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CFTSp048|A16281|2013-001812-30,2014-02,2018-01-05,2019-01,2013-08-20,,2020-01-28,"Queen Elizabeth Hospital, Birmingham, United Kingdom|Bristol Haematology & Oncology Centre, Bristol, United Kingdom|North Cumbria University Hospitals, Carlisle, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, G12 0YN, United Kingdom|Castle Hill Hospital, Hull, United Kingdom|St James' Hospital, Leeds, United Kingdom|Clatterbridge Cancer Centre, Liverpool, United Kingdom|Guy's and St Thomas' Hospital, London, United Kingdom|Hammersmith Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|University College London, London, United Kingdom|Maidstone Hospital, Maidstone, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|Southampton General Hospital, Southampton, United Kingdom",
